Production of blood typing reagents by the National Blood Centre, Thai Red Cross Society

Abstract

Monoclonal antibodies are known as proteins that can be biotherapeutic agents. As medicine moves into a new era of personalized medicine, the use of monoclonal antibodies to treat diseases is central to this new approach. Since the first monoclonal antibody was approved for clinical use 30 years ago, the monoclonal antibody industry has expanded rapidly and currentlyis worth a lot of money. Currently, the National Blood Centre, Thai Red Cross Society, has applied the knowledge of monoclonal antibodies to develop and successfully produce monoclonal antibody blood typing reagents, which provide significant benefits to blood banks. This review focuses on the history and development of blood typing reagents production at the National Blood Centre, Thai Red Cross Society. Monoclonal antibodies, which were developed from donor serum, have been shown to have superior properties and efficacy in all dimensions, including higher specificity and potency. The production of monoclonal antibodies requires experienced people, expertise, and great effort to achieve success and bring great benefits to the country, reducing the import of foreign reagents by more than tens of millions of baht per year. In the future, it is being researched to increase its maximum efficiency for use in blood banks.